A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women
Phase of Trial: Phase IV
Latest Information Update: 15 May 2017
At a glance
- Drugs Alendronic acid/colecalciferol (Primary) ; Alendronic acid
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Merck & Co
- 10 Jun 2017 Biomarkers information updated
- 07 Apr 2010 Patient numbers amended from 350 to 343 as reported by ClinicalTrials.gov.
- 05 Jun 2009 Actual initiation date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.